X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will accelerate the Company’s clinical development program and further build out its innovative retina pipeline, including intravitreal (IVT) Restoret, EYE103 in patients with diabetic macular edema and neovascular age-related macular degeneration.
Lead Product(s): EYE103
Therapeutic Area: Ophthalmology Product Name: EYE103
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bain Capital Life Sciences
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 14, 2023
Details:
Restoret (EYE103) is a tri-specific Wnt agonist antibody, built based on AntlerA’s ANT-Pharm technology. It is designed to address urgent unmet medical need in patients with back-of-the-eye diseases.
Lead Product(s): EYE103
Therapeutic Area: Ophthalmology Product Name: Restoret
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
